Digital Medicines to Measure Drug Ingestion Adherence

  • Naunihal S. VirdiEmail author
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)


Proteus Discover, a new digital medicine offering, provides a direct measure of medication ingestion adherence. The offering gives patients feedback on their performance via a mobile device application and allows providers to review patients’ medication adherence and activity. Digital medicines have been shown through clinical studies and real-world use to provide benefits for patients with diabetes and hypertension, as well as other diseases.


Digital medicines Digital health Adherence Hypertension Cardiometabolic Diabetes mellitus Mobile Patient engagement 



The author would like to acknowledge the following persons for their editorial support: Scooter Plowman, Betsy Klein, Praveen Raja, Melody Tran, George Savage, Lorenzo DiCarlo, Andrew Thompson, Maneesh Gupta, David O’Reilly, Manny Severino, and Lacey Kim.


  1. 1.
    Rohatagi S, Profit D, Hatch A, Zhao C, Docherty JP, Peters-Strickland TS. Optimization of a digital medicine system in psychiatry. J Clin Psychiatry. 2016;77(9):e1101–7. Scholar
  2. 2.
    Choudhry NK, Krumme AA, Ercole PM, Girdish C, Tong AY, Khan NF, Brennan TA, Matlin OS, Shrank WH, Franklin JM. Effect of reminder devices on medication adherence: the REMIND randomized clinical trial. JAMA Intern Med. 2017;177(5):624. Scholar
  3. 3.
    Choudhry NK, Krumme AA, Ercole PM, Girdish C, Isaman DL, Matlin OS, Brennan TA, Shrank WH, Franklin JM. Rationale and design of the randomized evaluation to measure improvements in non-adherence from low-cost devices (REMIND) trial. Contemp Clin Trials. 2015;43:53–9. Scholar
  4. 4.
    Kahneman D. Thinking, fast and slow. 1st ed. New York: Farrar, Straus and Giroux; 2011.Google Scholar
  5. 5.
    Hibbard JH, Greene J, Overton V. Patients with lower activation associated with higher costs; delivery systems should know their patients’ “scores”. Health Aff Proj Hope. 2013;32(2):216–22. Scholar
  6. 6.
    Remmers C, Hibbard J, Mosen DM, Wagenfield M, Hoye RE, Jones C. Is patient activation associated with future health outcomes and healthcare utilization among patients with diabetes? J Ambulatory Care Manage. 2009;32(4):320–7. Scholar
  7. 7.
    DiCarlo L, Moon G, Intondi A, Duck R, Frank J, Hafazi H, Behzadi Y, Robertson T, Costello B, Savage G, Zdeblick M. A digital health solution for using and managing medications: wirelessly observed therapy. IEEE Pulse. 2012;3(5):23–6. Scholar
  8. 8.
    Hafezi H, Robertson TL, Moon GD, Au-Yeung K-Y, Zdeblick MJ, Savage GM. An ingestible sensor for measuring medication adherence. IEEE Trans Biomed Eng. 2015;62(1):99–109. Scholar
  9. 9.
    Proteus digital health feedback device, instructions for use. Redwood City, CA: Proteus(r) Digital Health, Inc.; 2016.Google Scholar
  10. 10.
    Godbehere P, Wareing P. Hypertension assessment and management: role for digital medicine. J Clin Hypertens (Greenwich). 2014;16(3):235. Scholar
  11. 11.
    Noble K, Brown K, Medina M, Alvarez F, Young J, Leadley S, Kim Y, DiCarlo L. Medication adherence and activity patterns underlying uncontrolled hypertension: assessment and recommendations by practicing pharmacists using digital health care. J Am Pharm Assoc. 2016;56(3):310–5. Scholar
  12. 12.
    Naik R, Macey N, West RJ, Godbehere P, Thurston S, Fox R, Xiang W, Kim YA, Singh I, Leadley S, DiCarlo LA. First use of an ingestible sensor to manage uncontrolled blood pressure in primary practice: the UK hypertension registry. J Community Med Health Educ. 2017;7(1).
  13. 13.
    Frias J, Virdi N, Raja P, Kim Y, Savage G, Osterberg L. Effectiveness of digital medicines to improve clinical outcomes in patients with uncontrolled hypertension and type 2 diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial. J Med Internet Res 2017;19(7):e246. DOI: 10.2196/jmir.7833.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pidermann B, Park H, Bijlani A, Truscott A, Travis E, Purvance C. The first real-world clinical and health economic outcomes of a digital health offering in a patient population with cardiovascular and metabolic chronic diseases. J Manag Care Spec Pharm 2017;23(3-a):S68.Google Scholar
  15. 15.
    Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant. 2009;9(11):2597–606. Scholar
  16. 16.
    Zullig LL, Peterson ED, Bosworth HB. Ingredients of successful interventions to improve medication adherence. JAMA. 2013;310(24):2611–2. Scholar
  17. 17.
    Lin S, Melendez-Torres GJ. Systematic review of risk factors for nonadherence to TB treatment in immigrant populations. Trans R Soc Trop Med Hyg. 2016;110(5):268–80. Scholar
  18. 18.
    Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19(7):31–41.PubMedGoogle Scholar
  19. 19.
    Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med. 2015;20(3):255–65. Scholar
  20. 20.
    Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275–301. Scholar
  22. 22.
    Kane JM, Perlis RH, DiCarlo LA, Au-Yeung K, Duong J, Petrides G. First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. J Clin Psychiatry. 2013;74(6):e533–40. Scholar
  23. 23.
    Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, DiCarlo L, Reves R. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One. 2013;8(1):e53373. Scholar
  24. 24.
    Wirelessly Observed Therapy (WOT): a new paradigm in TB therapy monitoring | CROI conference. Accessed 25 Apr 2017.
  25. 25.
    Bonacini M, Kim YA, Reichert M, Travis E, Virdi N, Raja P, Savage G. Tu1659 a new digital health feedback offering to keep patients adherent to oral hepatitis C therapy. Gastroenterology. 2016;150(4):S1159. Scholar
  26. 26.
    Corris PA, Day M, Gibiansky M, Kim YA, DiCarlo L. A pilot study of digital feedback to guide therapeutic decisions in pulmonary hypertension. Eur Respir J. 2016;48(Suppl 60):PA2407.Google Scholar
  27. 27.
    Measuring and monitoring adherence to ART with pill ingestible sensor system—full text view. Accessed 9 May 2017.
  28. 28.
    Digital health feedback system for longitudinal measurement of medication adherence during initial ARV therapy—full text view. Accessed 9 May 2017.
  29. 29.
    Feasibility of an ingestible sensor system to measure PrEP adherence in YMSM—full text view. Accessed 9 May 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Proteus Digital HealthRedwood CityUSA

Personalised recommendations